BNET Industries

Market Cap:$1.8B
Last Fiscal Year Sales:$1.2B
  • Public
  • US
Dow Jones Description

We are a research-based pharmaceutical company focused on discovering, developing and commercializing differentiated products that address large and growing markets and unmet medical needs and are prescribed principally by primary care physicians and certain specialists. Our drug discovery and development program, together with our corporate development and licensing activities, have yielded a portfolio of products and product candidates intended to treat a broad range of indications. We are currently concentrating our product development efforts in two therapeutic areas: respiratory diseases and central nervous system, or CNS, disorders. In our isomer and metabolite development program, we identify existing drugs that might, in single-isomer or active-metabolite forms, provide significant advances over existing therapies within the indications of the existing drug or in new indications. We then develop isomers or metabolites designed to offer benefits over both the existing drug and competitive compounds, such as reduced side effects, improved therapeutic efficacy, effectiveness for new indications or improved dosage forms. Our development program for new chemical entities encompasses a more traditional approach to drug development. ...

President and Chief Executive OfficerAdrian Adams
Number of Employees 2,400
Contact Information

84 Waterford Dr

Marlborough, Massachusetts 01752

sepracor.com

(508) 481-6700

NAICS Code Pharmaceutical and Medicine Manufacturing: 3254

Recent Events

  • Sepracor, UCB file suit against Perrigo partner

    6/24/09 - Lawsuit Filed - View Story

  • BRIEF-RESEARCH ALERT-JP Morgan raises Sepracor to overweight

    5/04/09 - Bond / Stock Rating - View Story

  • Goldman Sachs Downgrades Sepracor SEPR to Sell

    5/01/09 - Bond / Stock Rating - View Story

  • Cephalon Q1 Profit Rises, Adj. EPS Beats Estimates; Guides Q2 and Backs FY09 Outlook -...

    5/05/09 - Financial Announcement - View Story

  • Pre-emption Rejection

    4/21/09 - Lawsuit Filed - View Story

  • Sepracor chairman unloads $8.7M shares

    3/23/09 - Legal Settlement - View Story

  • Sepracor, Inc. SEPR Reaches Xopenex Deal with Teva Pharmaceutical Industries Limited TEVA

    3/11/09 - Joint Venture / Alliance - View Story

  • Sepracor and Teva resolve patent infringement litigation

    3/12/09 - Legal Settlement - View Story

  • Zacks Upgrades and Revisions Strategy Highlights: UFP Technologies, Nuance Communications, NetScout Systems and Sepracor

    2/13/09 - Financial Announcement - View Story

  • Sepracor Reports Fourth Quarter and Full-Year 2008 Operating Results

    1/29/09 - Joint Venture / Alliance - View Story

  • U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting...

    1/12/09 - Lawsuit Filed - View Story

News & Analysis

sepracor inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Adrian Adams President and Chief Executive Officer
Douglas E. Reedich Chief Patent Counsel
Jose Sierra Senior Vice President, Chief Compliance Officer
Mark Iwicki Executive Vice President and Chief Commercial Officer
Robert Dishman Coo
Robert F. Scumaci Executive Vice President & Chief Financial Officer
Andrew I. Koven Executive Vice President, General Counsel and Corporate Secretary
Mark H.N. Corrigan MD Executive Vice President, Research and Development
Richard Ranieri Executive Vice President, Human Resources and Administration
Jonae R. Barnes Senior Vice President, Investor Relations & Corporate Communications
James M Roach Vice President of Medical Affairs
Stephen A. Wald Vice President, Chemical Res & Development
Barberich Timothy Founder
Robert L. Bratzler Co-Founder
Pat Latterell Partner
Gautam Shah Senior Director of Regulatory Affairs
Eric N Jacobsen Consultant
James G. Andress Director
Marshall B. Stamper Director

Board of Directors

Name (plus bio) Position
Timothy J. Barberich Chairman of the Board
Alan A. Steigrod Board of Directors
Amy P. Trevvett Board of Directors
Digby W. Barrios Board of Directors
James F. Mrazek Board of Directors
Keith Mansford Board of Directors
Lisa Ricciardi Board of Directors
Robert J. Wherry Board of Directors
Timothy J. Rink Board of Directors

Mr. Adams joined Sepracor in March 2007 as President and Chief Operating Officer and, in May 2007, became President and Chief Executive Officer of the company. Most recently, Mr. Adams was with Kos Pharmaceuticals, Inc., where he served as President and Chief Operating Officer from April 2001, prior to becoming President and Chief Executive Officer in January 2002. In December 2006, Mr. Adams was instrumental in the sale of Kos to Abbott Laboratories. Having spent the majority of his career in the pharmaceutical industry, Mr. Adams has extensive senior and general management experience with a broad background encompassing research and development, sales, marketing, international and national product management and business development. Mr. Adams served as President and Chief Executive Officer of Novartis-UK from 1999 until his tenure began at Kos. For the previous seven years, Mr. Adams was with SmithKline Beecham Pharmaceuticals, last serving as President and CEO of the company's Canadian subsidiaries. Previous assignments at SmithKline Beecham included Vice President and Director of Worldwide Marketing in the U.S., and Director and Vice President of Sales and Marketing in the United Kingdom. Mr. Adams began his career at ICI Pharmaceuticals, where he rose from research laboratory assistant to Director of Sales and Marketing. During his career, he has worked in most countries of the world and has experience in most primary care, specialist and biological therapeutic areas. In addition, he has been instrumental in a number of major global and national product launches including Paxil®, Famvir®, Coreg®, Diovan®, Tenormin® and Zestril®. He is a graduate of Manchester University in the United Kingdom with a Bachelor of Science degree. Mr. Adams serves as a board member of Amylin Pharmaceuticals.

Organization Position Status
Sepracor Inc. President and Chief Executive Officer Current
Sepracor Inc. Board of Directors Current
Amylin Pharmaceuticals, Inc. Board of Directors Current
Kos Pharmaceuticals, Inc. CEO Former
Kos Pharmaceuticals, Inc. President Former
Kos Pharmaceuticals, Inc. Coo Former
Sepracor Inc. President Former
Sepracor Inc. Coo Former
Manchester University Bachelor of Science Degree Former
Organization Position Status
Sepracor Inc. Chief Patent Counsel Current
Sepracor Inc. Senior Vice President, Legal Affairs Former
Organization Position Status
Sepracor Inc. Senior Vice President, Chief Compliance Officer Current

Mark Iwicki joined Sepracor in October 2007 and is Executive Vice President and Chief Commercial Officer. Mr. Iwicki is responsible for leading all aspects of Sepracor's Commercial functions, including the Sales, Marketing, Managed Care, New Products Planning, and Commercial Analytics groups. Prior to joining Sepracor, Mr. Iwicki held senior positions at Novartis Pharmaceuticals from 1998 through 2007, most recently as Vice President and Cardiovascular Business Franchise Head. Prior to that, Mr. Iwicki was head of the Arthritis, Bone, Gastrointestinal, HRT, Infectious Disease and Urology Business Franchise Head. Before joining Novartis, Mr. Iwicki held various sales and marketing positions at Merck and Astra Merck. Mr. Iwicki earned his B.S. from Ball State University and an MBA from Loyola College.

Organization Position Status
Sepracor Inc. Executive Vice President and Chief Commercial Officer Current
Infectious Disease Head Former
The Bone Head Former
Loyola College in Maryland MBA Former

Bob Dishman is a scientist with a long history as a successful biotech operating executive and entrepreneur. In the course of his 30+ years of experience, Bob has become recognized as a leading expert in running biotech companies engaged in drug discovery based on bioseparation, purification, and combinatorial chemistry. Bob is perhaps best known as COO of Sepracor, Inc., managing its work in the "pure isomer" form of major pharmaceuticals, and as the founder and CEO of Arqule, Inc., one of the early combinatorial chemistry companies, both of which went public and achieved multimillion dollar valuations. In addition, Bob was the President and Founder of the Milligen Division of Millipore, focused on DNA and peptide synthesizers and sequencers for analysis and synthesis of biological molecules, and CEO of Biotage, Inc., a company he helped re-direct and take public as Dyax Corp. More recently, Bob has been CEO, Chairman or Board member of four other biotech companies both public and private. Dr. Dishman holds a Ph.D. in Analytical Chemistry, a MS in Chemistry, both from the University of Massachusetts, Amherst, and a BS from the University of New Hampshire, Durham.

Organization Position Status
Sepracor Inc. Coo Current
Echelon Ventures, LLC Advisor Current
Xcellerex, Inc. Non-Executive Chairman Current
Harvard Bioscience, Inc. Board of Directors Current
Harvard Apparatus, Ltd. Director Current
Serenex, Inc. Chief Executive Officer Former
ArQule, Inc. CEO Former
Biotage Incorporated CEO Former
Dyax Corp. Executive Vice President Former
ArQule, Inc. Founder Former
Dyax Corp. consultant Former
Dyax Corp. Director Former

Mr. Scumaci was recently appointed as Executive Vice President and Chief Financial Officer of Sepracor. Mr. Scumaci served as Executive Vice President, Corporate Finance, Administration and Technical Operations since May 2007 and as Executive Vice President of Finance and Administration at Sepracor since February 2001. Mr. Scumaci served as Senior Vice President of Finance and Administration at Sepracor from March 1996 to February 2001 and as Vice President and Controller from March 1995 until March 1996. Prior to joining Sepracor, Mr. Scumaci was Vice President of Finance and Administration, North American Operations with Ares-Serono Group, a multinational pharmaceutical company from 1987 to 1994. Previously, he was associated with Revlon and Coopers & Lybrand in various finance and accounting capacities.

Organization Position Status
Sepracor Inc. Executive Vice President & Chief Financial Officer Current
Sepracor Inc. Senior Vice President of Finance and Administration Former
Revlon, Inc. Former
PricewaterhouseCoopers Former

Prior to joining Sepracor in March 2007, Mr. Koven was Executive Vice President, General Counsel and Corporate Secretary at Kos Pharmaceuticals, Inc., which was acquired by Abbott Laboratories in December 2006. At Kos, he oversaw the legal, compliance and quality assurance functions. From 2000 until 2003, Mr. Koven served as Senior Vice President, General Counsel and Corporate Secretary at Lavipharm Laboratories Inc., a drug delivery and specialty pharmaceutical company. Mr. Koven served in increasingly responsible roles at Warner-Lambert Company between 1993 and 2000, most recently in the position of Assistant General Counsel, Pharmaceuticals, North America. Prior to joining Warner-Lambert, Mr. Koven was a corporate/securities associate at Cahill Gordon & Reindel in New York City. Mr. Koven earned his B.A. in 1978 from Dalhousie University in Halifax, Nova Scotia, Canada, his LL.B. in 1981 from Dalhousie Law School and his LL.M. in 1986 from Columbia University School of Law.

Organization Position Status
Sepracor Inc. Executive Vice President, General Counsel and Corporate Secretary Current
Kos Pharmaceuticals, Inc. Executive Vice President Former
Kos Pharmaceuticals, Inc. General Counsel Former
Sepracor Inc. Corporate Secretary Former
Cahill Gordon & Reindel Llp Corporate, Securities Associate Former
Warner-Lambert Former
Columbia University Law School Ll.M Former

Dr. Corrigan joined Sepracor in 2003 as Executive Vice President of Research and Development. Prior to joining Sepracor, Dr. Corrigan joined the Upjohn Company in 1993, which became Pharmacia Corp. in 1996. At Pharmacia, Dr. Corrigan served as Group Vice President of Global Clinical Research and Experimental Medicine and in 1998, was promoted to Group Vice President, Global Clinical Research, with responsibility for clinical research, biostatistical/data management and global procurement for compounds in Phases I-IIIB. Prior to joining the pharmaceutical industry with the Upjohn Company, Dr. Corrigan spent several years in academic research at the University of North Carolina Medical School, focusing in psychoneuroendocrinology. During his tenure, Dr. Corrigan was a principal investigator for several novel antipsychotics and continues to maintain an appointment as Adjunct Clinical Professor of Psychiatry. Dr. Corrigan has over twenty years of experience in treating psychiatric and central nervous system disorders and is board certified in psychiatry and neurology. Dr. Corrigan earned his undergraduate and medical degrees from the University of Virginia and subsequently received specialty training in psychiatry at Cornell and Maine Medical Center. Dr. Corrigan serves as a board member of Cubist Pharmaceuticals, Inc. and Neuromed Technologies Inc. and has been elected as a Distinguished Fellow of the American Psychiatric Association (APA).

Organization Position Status
Sepracor Inc. Executive Vice President, Research and Development Current
Neuromed Pharmaceuticals, Inc. Board of Directors Current
Cubist Pharmaceuticals, Inc. Board of Directors Current
Pharmacia & Upjohn Group Vice President of Global Clinical Research Former
Pharmacia Corporation Group Vice President, Global Clinical Research and Experimental Medicine Former
Global Clinical Research Corp Group Vice President Former
Maine Medical Center Former
University of Virginia Undergraduate and Medical Degrees Former
University of Virginia Degrees Former

Mr. Ranieri joins Sepracor from Neurocrine Biosciences, Inc. where he was Senior Vice President and Chief Administrative Officer. Mr. Ranieri managed and directed Neurocrine Biosciences' human resources function and its corporate communications, operations and purchasing. He also served as a corporate officer and was a member of the senior management team as well as Secretary to the Compensation Committee of the Board of Directors. Prior to his tenure with Neurocrine Biosciences, Mr. Ranieri served as Senior Vice President, Human Resources at Genencor International Inc. for 12 years, contributing to its growth from a start-up to a publicly traded company with over 2,000 employees worldwide. Prior to joining Genencor, Mr. Ranieri spent over 13 years with GlaxoSmithKline where he held a variety of human resources and sales management positions. Mr. Ranieri earned his bachelor's degree from Villanova University and received his Master's degree in Organizational Development from Rider University.

Organization Position Status
Sepracor Inc. Executive Vice President, Human Resources and Administration Current
Big Brothers Big Sisters President Former
Neurocrine Biosciences, Inc. Chief Admin Officer & Senior Vice President Former
Neurocrine Biosciences, Inc. Senior Vice President, HR Former
Rider University Master's Degree In Organizational Development Former
Villanova University bachelor's degree Former
Organization Position Status
Sepracor Inc. Senior Vice President, Investor Relations & Corporate Communications Current
Organization Position Status
Sepracor Inc. Vice President of Medical Affairs Current
Georgetown University School of Medicine Degree Former
Organization Position Status
Sepracor Inc. Vice President, Chemical Res & Development Current
Organization Position Status
Sepracor Inc. Founder Current
Sepracor Inc. Chairman Current
Point Therapeutics Director Current
Heartware International, Inc. Director Current
Sepracor Inc. Chief Executive Officer Former
Sepracor Inc. President Former
Sepracor Inc. Director Former
Organization Position Status
Sepracor Inc. Co-Founder Current
Cancer Immunity Board of Directors Current
Coley Pharmaceutical Group Inc. President & CEO Former
Coley Pharmaceutical Group Inc. Board of Directors Former
Massachusetts Institute of Technology Ph.D. in chemical engineering Former
Massachusetts Institute of Technology Ph.D. in chemical engineering Former
University of Michigan B.S. degree Former

Patrick F. Latterell has served on our Board since July 2002. Mr. Latterell is the founder of Latterell Venture Partners, a venture capital firm, and has served as the Managing Member of its general partner entities since 2001. Prior to forming Latterell Venture Partners, Mr. Latterell was a General Partner at Venrock Associates, which he joined in 1989. Mr. Latterell served as Chairman of the National Venture Capital Association Medical Industry Group in 2003 and 2004, and also serves on the boards of several privately-held medical device companies. Mr. Latterell holds an S.B. in Biological Sciences and an S.B. in Economics from the Massachusetts Institute of Technology, and an M.B.A. from Stanford University.

Organization Position Status
Latterell Venture Partners Founder Current
Geron Corporation Partner Current
CardioThoracic Systems, Inc. Partner Current
Pharmacyclics, Inc. Partner Current
Vical Incorporated Partner Current
Sepracor Inc. Partner Current
PerSeptive BioSystems, Inc. Partner Current
Isis Pharmaceuticals, Inc. Partner Current
Xtent Inc. Board of Directors Current
Venrock Associates General Partner Former
Latterell Venture Partners founded Former
Stanford Graduate School of Business MBA Former
Massachusetts Institute of Technology SB degrees in biological sciences and economics Former
Stanford University M.B.A. Former
Stanford University S.B. In Biological Sciences Former
Organization Position Status
Achillion Pharmaceuticals, Inc Senior Vice President and Chief Compliance Officer Current
Sepracor Inc. Senior Director of Regulatory Affairs Current
Achillion Pharmaceuticals, Inc Vice President, Regulatory Affairs Former
University of Illinois Degree In Pharmaceutics Former
Organization Position Status
Sepracor Inc. Consultant Current
PTC Therapeutics, Inc Board of Directors Current
University of California, Berkeley Ph.D. In Organometallic Chemistry Former

Mr. Barberich has served as Chairman of our Board of Directors since 1990. He served as our President from 1984 to 1990, and as our Chief Executive Officer from 1984 until May 2007. From May 2007 until May 2008, Mr. Barberich served as our Executive Chairman. From 1984 until October 1999, Mr. Barberich also served as our President. Mr. Barberich serves as a director of BioSphere Medical, Inc. and HeartWare Limited, which are publicly traded entities, and Gem X Biotechnologies, Resolvyx Pharmaceuticals, Inc., Bionevia Pharmaceuticals, Inc. and Boston Medical Center, which are privately held entities.

Organization Position Status
Sepracor Inc. Chairman of the Board Current
Pharmaceutical Research and Manufacturers of America Chairman Current
Gemin X, Inc. Executive Chairman of The Board of Directors Current
PhRMA Director Current
BioSphere Medical, Inc. Board Member Current
Lung Cancer Caring Ambassadors Program Director Current
Worcester Business Journal Board of Directors Current
HeartWare Limited Board of Directors Current
Sepracor Inc. CEO Former
Boehringer Ingelheim Corporation CEO Former
Sepracor Inc. President Former
Sepracor Inc. Founder Former
Point Therapeutics Board Member Current
Vicuron Pharmaceuticals Inc. Former
Millipore Corporation Former
Pfizer Inc. Former
BioSphere Medical, Inc. Executive Chairman Former
King's College B.S. Degree In Chemistry Former
Organization Position Status
Lorus Therapeutics Inc. Managing Director of Newport Healthcare Ventures Current
University Kidney Disease Research Associates Alan A. Steigrod Is Managing Director of Newport Healthcare Ventures Current
Lindora, Inc. Advisor Current
Lorus Therapeutics Inc. Director Current
University Kidney Disease Research Associates Director Current
NeoRx Corporation Board of Directors Current
Sepracor Inc. Board of Directors Current
Cortex Pharmaceuticals, Inc. Chief Executive Officer Former
Cortex Pharmaceuticals, Inc. President Former
Organization Position Status
Sepracor Inc. Board of Directors Current

Digby W. Barrios, age 71, has been a director since 1992 and currently serves on both our Compensation Committee and Nominating and Corporate Governance Committee. Since July 1992, Mr. Barrios has been an independent management consultant. From 1988 until June 1992, Mr. Barrios served as President and Chief Executive Officer of Boehringer Ingelheim Corporation, a fine chemical and pharmaceutical company.

Organization Position Status
Sepracor Inc. Board of Directors Current
Boehringer Ingelheim Corporation CEO Former
Boehringer Ingelheim Corporation President Former

James F. Mrazek, age 68, has been a director since 1984 and currently serves on both our Compensation Committee and Audit Committee. Mr. Mrazek served as the Chairman of our Board of Directors from 1984 until 1990. Since March 1996, Mr. Mrazek has served as Managing Partner of the Four Corners Venture Fund, a venture capital and management consulting firm. From January 1990 until March 1996, Mr. Mrazek was President of Carnegie Venture Resources, a venture capital and management consulting firm.

Organization Position Status
Sepracor Inc. Board of Directors Current
Sepracor Inc. Chairman of the Board Former
Organization Position Status
Sepracor Inc. Director Current
The Allstate Corporation Board of Directors Current
XOMA Corporation Director Current
Warner Chilcott Plc Chief Executive Officer Former
Sterling Drug President Former
Warner Chilcott Plc President Former
Sterling Drug Coo Former
Care and Company Former
Warner Chilcott Plc Chairman Former
Dade Behring Holdings, Inc. Board of Directors Former

Dr. Mansford is a Principle of Mansford Associates, a leading consulting group serving the international biotechnology and pharmaceutical industries, and is currently a non-executive director of Sepracor, Inc. Formerly, he was head of R&D and a group board member of SmithKlineBeecham. Dr. Mansford has held non-executive directorships at SkyePharma, Kudos Pharmaceuticals and Proteome Sciences.

Organization Position Status
Sepracor Inc. Board of Directors Current
Mindset Biopharmaceuticals Ltd. Board of Directors Current
Sepracor Inc. External Director Former
Skyepharma, Inc. Non-Executive Director Former
SmithKline Beecham Corporation Head of R&D Former
Protemix Corporation Chairman of Protemix's Board of Directors Former
GlaxoSmithKline Plc Chairman of Research and Development Former
SmithKline Beecham Corporation Board Member Former
University of London Ph.D in biochemistry Former

Lisa Ricciardi, age 49, has been a director since November 2007 and currently serves on our Compensation Committee. Since October 2007, Ms. Ricciardi has been an Adjunct Partner at Essex Woodlands Health Ventures, a venture capital firm. Prior to joining Essex Woodlands Health Ventures, Ms. Ricciardi was Senior Vice President of Licensing and Development for Pfizer, Inc., a pharmaceutical company, a position to which she was promoted in 2004 after serving as Vice President for Licensing and Development beginning in 1998.

Organization Position Status
Sepracor Inc. Board of Directors Current

Marshall B. Stamper, M.D. is a pioneer in the study of obesity and is the founder of Lindora, California's largest weight management organization. A graduate of the University of Mississippi School of Medicine, he established a general medical practice in California, where he became interested in the study of obesity and became one of the first physicians to specialize in bariatrics, the treatment of obesity. Alan A. Steigrod has been an advisor to the Board of Directors since 1996. Since 1996 Mr. Steigrod has served as Managing Director of Newport HealthCare Ventures, a venture capital and consulting firm. From March 1993 until November 1995, Mr. Steigrod served as President and Chief Executive Officer of Cortex Pharmaceuticals Inc. From February 1991 until February 1993, Mr. Steigrod was a management consultant. From March 1981 until February 1991, Mr. Steigrod served as Executive Vice President of Marketing/Sales of Glaxo Inc., a pharmaceutical corporation. Mr. Steigrod also serves as a director of NeoRx Corporation, Lorus Therapeutics Inc., and Sepracor, Inc.

Organization Position Status
Lindora, Inc. Founder Current
Lindora, Inc. Dr Current
NeoRx Corporation Director Current
Lindora, Inc. Board of Directors Current
Lorus Therapeutics Inc. Director Current
Sepracor Inc. Director Current
Cortex Pharmaceuticals, Inc. President and Chief Executive Officer Former
University of Mississippi School of Medicine Former

Robert J. Wherry is the Senior Director, Computer Systems Compliance for Sepracor Inc. and has been employed in the pharmaceutical industry for over 20 years. He has worked in the areas of process development, process validation, computer validation, regulatory affairs, regulatory operations, quality assurance and corporate compliance within the pharmaceutical and biotechnology industries. Bob has lectured extensively on process validation, computer validation, biotechnology, regulatory affairs and quality assurance issues at numerous conferences. He has authored on sterility assurance validation and computer validation, and has also contributed to the editing of several computer validation publications. Bob holds a B.S in Chemical Engineering from Lehigh University.

Organization Position Status
Sepracor Inc. Board of Directors Current
Organization Position Status
Amylin Pharmaceuticals, Inc. Board of Directors Current
Sepracor Inc. Board of Directors Current
Santhera Pharmaceuticals AG Board of Directors Current
Biovex, Inc. Board of Directors Current
Amylin Pharmaceuticals, Inc. Member Current
Aurora Biosciences Corporation Chief Executive Officer Former
Amylin Pharmaceuticals, Inc. President Former
Aurora Biosciences Corporation Chief Executive Former
Amylin Pharmaceuticals, Inc. Chief Technical Officer Former
GlaxoSmithKline Plc Vice President for Research Former
University of Cambridge Lecturer in Physiology Former
Aurora Biosciences Corporation Chairman Former
Solexa, Inc. chairman Former
Cambridge University Degrees Former

Executive News

  • Amylin Pharmaceuticals, Inc. (AMLN) Announces Preliminary Tabulation of Annual Meeting Results

    BioSpace - 6/02/09 - View Story

  • Amylin (AMLN) Reports Preliminary Tabulation of Annual Meeting Results

    Street Insider - 6/02/09 - View Story

  • Amylin Announces Preliminary Tabulation of Annual Meeting Results

    TradingMarkets - 6/02/09 - View Story

  • Amylin Pharma Announces Preliminary Tabulation of Annual Meeting Results - Quick Facts

    RTTNews.com - 6/02/09 - View Story

  • Amylin Announces Preliminary Tabulation of Annual Meeting Results

    PR Newswire via Yahoo! - 6/02/09 - View Story

  • Amylin Announces Preliminary Tabulation of Annual Meeting Results

    Yahoo! Canada - 6/02/09 - View Story

  • Amylin Announces Preliminary Tabulation of Annual Meeting Results

    Street Insider - 6/02/09 - View Story

  • Amylin Announces Preliminary Tabulation of Annual Meeting Results

    Stockwatch - 6/02/09 - View Story

  • Sepracor's STEDESA (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA

    Pharma Live - 6/01/09 - View Story

  • Sepracor`s STEDESAâ„¢ (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA

    Reuters - 6/01/09 - View Story

  • Sepracors STEDESA„ (Eslicarbazepine Acetate) New Drug Application Formally Accepted for Review by the FDA

    Business Wire - 6/01/09 - View Story

  • Sepracor advances epilepsy drug

    Boston Business Journal - 6/01/09 - View Story

advertisement
     SEPR $14.67 -3.22 (-18.00% )
Average Volume 2,056,420
Shares Outstanding 109.30M
Market Cap 1.6B
Year High 22.25
Year Low 9.83
Earnings Per Share N/A
P/E Ratio -
Dividend N/A
Yield N/A
advertisement